This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2019 Jan 15;10(5):617.

doi: 10.18632/oncotarget.26610.

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

Nikhil Patkar¹, Rohan Kodgule^{1

2}, Chinmayee Kakirde¹, Goutham Raval¹, Prasanna Bhanshe¹, Swapnali Joshi¹, Shruti Chaudhary¹, Y Badrinath¹, Sitaram Ghoghale¹, Shraddha Kadechkar¹, Syed Hasan Khizer³, Sadhana Kannan⁴, Dhanalaxmi Shetty⁵, Anant Gokarn³, Sachin Punatkar³, Hasmukh Jain³, Bhausaheb Bagal³, Hari Menon⁶, Manju Sengar³, Navin Khattry³, Prashant Tembhare¹, Papagudi Subramanian¹, Sumeet Gujral¹

Affiliations

Affiliations

¹ Haematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
² Homi Bhabha National Institute, Training School Complex, Mumbai, India.
³ Adult Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India.
⁴ Biostatistics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
⁵ Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
⁶ Haemato-Oncology, CyteCare Cancer Hospital, Bangalore, India.

PMID: 30728913
PMCID: PMC6355171
DOI: 10.18632/oncotarget.26610

Published Erratum

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

Nikhil Patkar et al. Oncotarget. 2019.

. 2019 Jan 15;10(5):617.

doi: 10.18632/oncotarget.26610.

Authors

Nikhil Patkar¹, Rohan Kodgule^{1

2}, Chinmayee Kakirde¹, Goutham Raval¹, Prasanna Bhanshe¹, Swapnali Joshi¹, Shruti Chaudhary¹, Y Badrinath¹, Sitaram Ghoghale¹, Shraddha Kadechkar¹, Syed Hasan Khizer³, Sadhana Kannan⁴, Dhanalaxmi Shetty⁵, Anant Gokarn³, Sachin Punatkar³, Hasmukh Jain³, Bhausaheb Bagal³, Hari Menon⁶, Manju Sengar³, Navin Khattry³, Prashant Tembhare¹, Papagudi Subramanian¹, Sumeet Gujral¹

Affiliations

¹ Haematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
² Homi Bhabha National Institute, Training School Complex, Mumbai, India.
³ Adult Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India.
⁴ Biostatistics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
⁵ Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
⁶ Haemato-Oncology, CyteCare Cancer Hospital, Bangalore, India.

PMID: 30728913
PMCID: PMC6355171
DOI: 10.18632/oncotarget.26610

Abstract

[This corrects the article DOI: 10.18632/oncotarget.26400.].

PubMed Disclaimer

Erratum for

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.
Patkar N, Kodgule R, Kakirde C, Raval G, Bhanshe P, Joshi S, Chaudhary S, Badrinath Y, Ghoghale S, Kadechkar S, Khizer SH, Kannan S, Shetty D, Gokarn A, Punatkar S, Jain H, Bagal B, Menon H, Sengar M, Khattry N, Tembhare P, Subramanian P, Gujral S. Patkar N, et al. Oncotarget. 2018 Nov 27;9(93):36613-36624. doi: 10.18632/oncotarget.26400. eCollection 2018 Nov 27. Oncotarget. 2018. PMID: 30564301 Free PMC article.

Similar articles

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
Forghieri F, Comoli P, Marasca R, Potenza L, Luppi M. Forghieri F, et al. Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492. Int J Mol Sci. 2018. PMID: 30404199 Free PMC article. Review.
Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
Blombery P, Jones K, Doig K, Ryland G, McBean M, Thompson E, Yannakou CK, Westerman D. Blombery P, et al. Arch Pathol Lab Med. 2018 May;142(5):606-612. doi: 10.5858/arpa.2017-0229-OA. Epub 2018 Feb 9. Arch Pathol Lab Med. 2018. PMID: 29425073
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J, Beinicke S, Häntschel J, Cross M, Vucinic V, Pönisch W, Behre G, Franke GN, Lange T, Niederwieser D, Schwind S. Bill M, et al. Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22. Ann Hematol. 2018. PMID: 29785446
Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M, Pettersson L. Ehinger M, et al. APMIS. 2019 May;127(5):337-351. doi: 10.1111/apm.12926. Epub 2019 Mar 28. APMIS. 2019. PMID: 30919505 Review.
Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL. Zhou Y, et al. Biol Blood Marrow Transplant. 2018 Aug;24(8):1615-1620. doi: 10.1016/j.bbmt.2018.04.017. Epub 2018 Apr 21. Biol Blood Marrow Transplant. 2018. PMID: 29684564

See all similar articles

Publication types

Actions

LinkOut - more resources

Full Text Sources